Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 143

1.

Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.

Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, Casali PG, Italiano A, Gutierrez A, Moura DS, Peña-Chilet M, Diaz-Martin J, Biscuola M, Taron M, Collini P, Ranchere-Vince D, Garcia Del Muro X, Grignani G, Dumont S, Martinez-Trufero J, Palmerini E, Hindi N, Sebio A, Dopazo J, Dei Tos AP, LeCesne A, Blay JY, Cruz J.

Lancet Oncol. 2019 Jan;20(1):134-144. doi: 10.1016/S1470-2045(18)30676-4. Epub 2018 Dec 18.

PMID:
30578023
2.

[Molecular biology of castration resistant prostate cancer.]

Medina-López RA, Tarón M, Osman-García I, Duran I.

Arch Esp Urol. 2018 Sep;71(8):639-650. Review. Spanish.

PMID:
30319124
3.

Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma.

Alemany R, Moura DS, Redondo A, Martinez-Trufero J, Calabuig S, Saus C, Obrador-Hevia A, Ramos R, Villar VH, Valverde C, Vaz MA, Medina J, Felipe-Abrio I, Hindi N, Taron M, Martin-Broto J.

Clin Cancer Res. 2018 Nov 1;24(21):5239-5249. doi: 10.1158/1078-0432.CCR-18-0851. Epub 2018 Jul 23.

PMID:
30037815
4.

Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.

Moura DS, Ramos R, Fernandez-Serra A, Serrano T, Cruz J, Alvarez-Alegret R, Ortiz-Duran R, Vicioso L, Gomez-Dorronsoro ML, Garcia Del Muro X, Martinez-Trufero J, Rubio-Casadevall J, Sevilla I, Lainez N, Gutierrez A, Serrano C, Lopez-Alvarez M, Hindi N, Taron M, López-Guerrero JA, Martin-Broto J.

Oncotarget. 2018 Apr 3;9(25):17576-17588. doi: 10.18632/oncotarget.24799. eCollection 2018 Apr 3.

5.

Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma.

Garrigós C, Espinosa M, Salinas A, Osman I, Medina R, Taron M, Molina-Pinelo S, Duran I.

Oncotarget. 2017 Nov 20;8(63):106551-106564. doi: 10.18632/oncotarget.22533. eCollection 2017 Dec 5.

6.

Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).

Martin-Broto J, Redondo A, Valverde C, Vaz MA, Mora J, Garcia Del Muro X, Gutierrez A, Tous C, Carnero A, Marcilla D, Carranza A, Sancho P, Martinez-Trufero J, Diaz-Beveridge R, Cruz J, Encinas V, Taron M, Moura DS, Luna P, Hindi N, Lopez-Pousa A.

Ann Oncol. 2017 Dec 1;28(12):2994-2999. doi: 10.1093/annonc/mdx536.

PMID:
29045512
7.

Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.

Bonanno L, Costa C, Majem M, Sanchez JJ, Rodriguez I, Gimenez-Capitan A, Molina-Vila MA, Vergnenegre A, Massuti B, Favaretto A, Rugge M, Pallares C, Taron M, Rosell R.

BMC Cancer. 2016 May 14;16:312. doi: 10.1186/s12885-016-2339-5.

8.

Aberrant gene methylation and bronchial dysplasia in high risk lung cancer patients.

Rosell A, Rodríguez N, Monsó E, Taron M, Millares L, Ramírez JL, López-Lisbona R, Cubero N, Andreo F, Sanz J, Llatjós M, Llatjós R, Fernández-Figueras MT, Mate JL, Català I, Setó L, Roset M, Díez-Ferrer M, Dorca J.

Lung Cancer. 2016 Apr;94:102-7. doi: 10.1016/j.lungcan.2016.02.003. Epub 2016 Feb 11.

PMID:
26973214
9.

Carcinosarcoma of the upper urinary tract with an aggressive angiosarcoma component.

Cuadra-Urteaga JL, Font A, Tapia G, Areal J, Taron M.

Cancer Biol Ther. 2016;17(3):233-6. doi: 10.1080/15384047.2016.1139237. Epub 2016 Feb 18.

10.

Pharmacogenetics and pharmacogenomics as tools in cancer therapy.

Rodríguez-Vicente AE, Lumbreras E, Hernández JM, Martín M, Calles A, Otín CL, Algarra SM, Páez D, Taron M.

Drug Metab Pers Ther. 2016 Mar;31(1):25-34. doi: 10.1515/dmpt-2015-0042. Review.

11.

Total Synthesis of Amphirionin-4.

Holmes M, Kwon D, Taron M, Britton R.

Org Lett. 2015 Aug 7;17(15):3868-71. doi: 10.1021/acs.orglett.5b01844. Epub 2015 Jul 14.

PMID:
26172382
12.

Pharmacogenomic biomarkers for personalized cancer treatment.

Rodríguez-Antona C, Taron M.

J Intern Med. 2015 Feb;277(2):201-217. doi: 10.1111/joim.12321. Review.

13.

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.

Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R.

Cancer Treat Rev. 2014 Sep;40(8):990-1004. doi: 10.1016/j.ctrv.2014.05.009. Epub 2014 Jun 6. Review.

PMID:
24953979
14.

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rolfo C, Pallarès MC, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina MA, Taron M.

Lung Cancer. 2014 May;84(2):161-7. doi: 10.1016/j.lungcan.2014.02.011. Epub 2014 Mar 2.

PMID:
24636848
15.

Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.

Benlloch S, Botero ML, Beltran-Alamillo J, Mayo C, Gimenez-Capitán A, de Aguirre I, Queralt C, Ramirez JL, Ramón y Cajal S, Klughammer B, Schlegel M, Bordogna W, Chen D, Zhang G, Kovach B, Shieh F, Palma JF, Wu L, Lawrence HJ, Taron M.

PLoS One. 2014 Feb 25;9(2):e89518. doi: 10.1371/journal.pone.0089518. eCollection 2014.

16.

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.

Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R.

Clin Cancer Res. 2014 Apr 1;20(7):2001-10. doi: 10.1158/1078-0432.CCR-13-2233. Epub 2014 Feb 3.

17.

Molecular profiles of non-small cell lung cancers in cigarette smoking and never-smoking patients.

Szymanowska-Narloch A, Jassem E, Skrzypski M, Muley T, Meister M, Dienemann H, Taron M, Rosell R, Rzepko R, Jarząb M, Marjański T, Pawłowski R, Rzyman W, Jassem J.

Adv Med Sci. 2013;58(2):196-206. doi: 10.2478/ams-2013-0025.

PMID:
24451080
18.

The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.

Bonanno L, Costa C, Majem M, Sanchez JJ, Gimenez-Capitan A, Rodriguez I, Vergnenegre A, Massuti B, Favaretto A, Rugge M, Pallares C, Taron M, Rosell R.

Oncotarget. 2013 Oct;4(10):1572-81.

19.

A prognostic DNA methylation signature for stage I non-small-cell lung cancer.

Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A, Sanchez-Cespedes M, Assenov Y, Müller F, Bock C, Taron M, Mora J, Muscarella LA, Liloglou T, Davies M, Pollan M, Pajares MJ, Torre W, Montuenga LM, Brambilla E, Field JK, Roz L, Lo Iacono M, Scagliotti GV, Rosell R, Beer DG, Esteller M.

J Clin Oncol. 2013 Nov 10;31(32):4140-7. doi: 10.1200/JCO.2012.48.5516. Epub 2013 Sep 30.

20.

EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study.

Hubers AJ, Heideman DA, Yatabe Y, Wood MD, Tull J, Tarón M, Molina MA, Mayo C, Bertran-Alamillo J, Herder GJ, Koning R, Sie D, Ylstra B, Meijer GA, Snijders PJ, Witte BI, Postmus PE, Smit EF, Thunnissen E.

Lung Cancer. 2013 Oct;82(1):38-43. doi: 10.1016/j.lungcan.2013.07.011. Epub 2013 Aug 5.

PMID:
23927883

Supplemental Content

Loading ...
Support Center